Osteodystrophy Uremic

Uremic osteodystrophy (OU) is a pathological condition of the skeletal system that develops in chronic renal failure, especially in the terminal stage of the disease. This condition is also known as osteodystrophy associated with renal failure or osteodystrophy uremic.

With OU, mineral metabolism in bone tissue is disrupted, which leads to changes in its structure and function. This can manifest as osteopenia (decreased bone density), osteosclerosis (increased bone density), osteomalacia (softening of bone tissue) and osteitis (inflammation of bone tissue). In addition, OU can cause disturbances in calcium and phosphorus metabolism, which can lead to the development of cardiovascular diseases.

Uremic osteodystrophy is one of the most common complications of chronic renal failure. It can lead to a deterioration in patients' quality of life and an increased risk of complications such as bone fractures. Treatment of OU is aimed at correcting impaired mineral metabolism, as well as treating the underlying disease that caused renal failure.

Treatment for OU is based on diet therapy and medications that help restore the correct balance of calcium and phosphorus in the body. In addition, vitamin D therapy may be prescribed to promote calcium absorption in the intestines. In some cases, hemodialysis or kidney transplantation may be required to improve kidney function and correct impaired mineral metabolism.

In conclusion, uremic osteodystrophy is a serious complication of chronic renal failure that can lead to a deterioration in the quality of life of patients and an increased risk of complications. Treatment of OU is aimed at correcting impaired mineral metabolism and the underlying disease that caused renal failure. Early detection and treatment of OU can help prevent the development of serious complications and improve the prognosis of the disease.